Mixed Hyperlipemia, Primary Hypercholesterolemia
Conditions
Brief summary
The study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with hypercholesterolemia and hyperlipemia.
Interventions
DRUGSHR-1209
SHR-1209
DRUGSHR-1209 Placebo
SHR-1209 Placebo
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
SHR-1209 monotherapy
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 and ≤80 on the date of signing the informed consent, male or female; 2. Fasting LDL-C was ≥2.6mmol/L and \<4.9mmol/L at screening and randomization； 3. Those who understand the study procedures and methods, volunteer to participate in the study, and sign the informed consent in person.
Exclusion criteria
1. Have the following diseases or treatment history :(1) Have known allergic reaction to experimental drugs, or have severe allergic reaction to other antibody drugs;(2) previous diagnosis of cardiac function as defined by the New York Heart Association (NYHA) grade III-IV; 2. Any of the laboratory indicators met the following criteria at screening or at random :(1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding 2 times the upper limit of normal (ULN), or total bilirubin exceeding 1.5 times the upper limit of normal (ULN);(2) Creatine kinase (CK) exceeds 3 times the upper limit of normal value (ULN); 3. General conditions :(1) the investigator judged that subcutaneous injection was not appropriate;(2) Fertile female subjects who did not use contraception within 4 weeks before screening;Or male or female subjects who do not agree to use high-efficiency contraceptives during the trial and for 24 weeks after the last dosing;(3) Women who are pregnant or lactating. 4. The Investigator determines that the subjects have poor compliance or have any factors that may prevent them from participating in the study, including, but not limited to, the study placing the subjects at unacceptable risk or possibly interfering with the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 12-weeks or 16weeks Percentage change in LDL-C relative to baseline | 12-weeks or 16weeks |
Secondary
| Measure | Time frame |
|---|---|
| 12-weeks or 16weeks change in LDL-C relative to baseline； | 12-weeks or 16weeks |
| Percentage of changes in non-HDL-C, ApoB, TC/HDL-C, ApoB/ApoA1, LP (a) and TG relative to baseline and relative to baseline after 12 weeks or 16 weeks of treatment | 12 weeks or 16 weeks |
Countries
China
Outcome results
None listed